Cat. No.: HY-18998

LMK-235

31 Cited Publications

Avis client

Based on 31 publication(s) in Google Scholar

LMK-235 is a potent and selective HDAC4/5 inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC₅₀s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.25%
CAS No.: 1418033-25-6
Formule: C₁₅H₂₂N₂O₄
Masse moléculaire:294.35

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

LMK-235 Chemical Structure

CAS No.: 1418033-25-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (31)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]

HDAC5

4.22 nM (IC₅₀)

HDAC4

11.9 nM (IC₅₀)

HDAC6

55.7 nM (IC₅₀)

HDAC1

320 nM (IC₅₀)

HDAC11

852 nM (IC₅₀)

HDAC2

881 nM (IC₅₀)

HDAC8

1278 nM (IC₅₀)

Voir tous les produits spécifiques à Isoform HDAC :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.17 μM Compound: 5; LMK235	Inhibition of HDAC in human A2780 cells Inhibition of HDAC in human A2780 cells	[PMID: 31787463]
A2780	IC₅₀	0.32 μM Compound: 19i, LMK235	Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	0.32 μM Compound: 19i, LMK235	Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A2780	IC₅₀	0.49 μM Compound: 19i, LMK235	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	0.65 μM Compound: 19i, LMK235	Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A2780	IC₅₀	0.97 μM Compound: 5; LMK235	Cytotoxicity against human A2780 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability by MTT assay	[PMID: 31787463]
CAL-27	IC₅₀	0.36 μM Compound: 19i, LMK235	Inhibition of HDAC in cisplatin resistant human CAL27 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human CAL27 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
CAL-27	IC₅₀	0.36 μM Compound: 19i, LMK235	Inhibition of HDAC in cisplatin sensitive human CAL27 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin sensitive human CAL27 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
CAL-27	IC₅₀	0.55 μM Compound: 5; LMK235	Inhibition of HDAC in human Cal27 cells Inhibition of HDAC in human Cal27 cells	[PMID: 31787463]
CAL-27	IC₅₀	0.76 μM Compound: 5; LMK235	Cytotoxicity against human CAL27 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human CAL27 cells assessed as reduction in cell viability by MTT assay	[PMID: 31787463]
CAL-27	IC₅₀	1.03 μM Compound: 19i, LMK235	Cytotoxicity against cisplatin sensitive human CAL27 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin sensitive human CAL27 cells after 72 hrs by MTT assay	[PMID: 23252603]
CAL-27	IC₅₀	1.81 μM Compound: 19i, LMK235	Cytotoxicity against cisplatin resistant human CAL27 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human CAL27 cells after 72 hrs by MTT assay	[PMID: 23252603]
HepG2	IC₅₀	0.16 μM Compound: 1a, LMK235	Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs	[PMID: 24904967]
HepG2	IC₅₀	1.26 μM Compound: 1a, LMK235	Cytotoxicity against human HepG2 cells after 48 hrs Cytotoxicity against human HepG2 cells after 48 hrs	[PMID: 24904967]
KYSE-510	IC₅₀	0.35 μM Compound: 19i, LMK235	Inhibition of HDAC in cisplatin resistant human KYSE-510 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human KYSE-510 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
KYSE-510	IC₅₀	1 μM Compound: 19i, LMK235	Inhibition of HDAC in cisplatin sensitive human KYSE-510 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin sensitive human KYSE-510 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
KYSE-510	IC₅₀	2.48 μM Compound: 19i, LMK235	Cytotoxicity against cisplatin resistant human KYSE-510 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human KYSE-510 cells after 72 hrs by MTT assay	[PMID: 23252603]
KYSE-510	IC₅₀	2.96 μM Compound: 19i, LMK235	Cytotoxicity against cisplatin sensitive human KYSE-510 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin sensitive human KYSE-510 cells after 72 hrs by MTT assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	0.41 μM Compound: 19i, LMK235	Inhibition of HDAC in cisplatin resistant human MDA-MB-231 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human MDA-MB-231 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	0.46 μM Compound: 19i, LMK235	Inhibition of HDAC in cisplatin sensitive human MDA-MB-231 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin sensitive human MDA-MB-231 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	1.37 μM Compound: 19i, LMK235	Cytotoxicity against cisplatin sensitive human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin sensitive human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23252603]
MDA-MB-231	IC₅₀	1.68 μM Compound: 19i, LMK235	Cytotoxicity against cisplatin resistant human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23252603]

In Vitro

LMK-235 shows cytotoxic activity against human ovarian cancer cell lines A2780 and A2780 CisR, with IC₅₀s of 0.49 μM and 0.32 μM, respectively. LMK-235 inhibits HDAC in A2780 and A2780 CisR cell lines, with IC₅₀s of 0.65 μM and 0.32 μM, respectively. LMK-235 produces a higher reduction in cell viability in comparison to the combination of cisplatin and vorinostat in all cell lines^[1]. LMK-235 (0, 0.625, 1.25, 2.5, 5, 10, and 20 μM) reduces the proliferation of BC cells in a dose- and time-dependent manner. LMK-235 (0-800 nM) also inhibits the growth of BC cells. Moreover, LMK-235 synergizes with bortezomib in BC cell lines^[2]. LMK235 (2, 20 nM) decreases in HDAC4 nuclear accumulation in Cdkl5 -/Y NPCs, completely restores the reduced number of neurons generated from Cdkl5 -/Y NPCs. LMK235 also restores histone 3 acetylation in Cdkl5 -/Y NPCs. LMK235 causes a notable increase in the isoform IV, but does not affect BDNF isoforms I or II^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LMK235 (5 and 20 mg/kg) restores survival and maturation of postmitotic granule neurons in Cdkl5 -/Y mice. LMK235 also restores synapse development in the dentate gyrus and hippocampus of Cdkl5 -/Y mice. Furthermore, LMK235 restores hippocampus-dependent learning and memory in Cdkl5 -/Y mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1418033-25-6
Appearance Solid
Masse moléculaire 294.35
Formule C₁₅H₂₂N₂O₄
Color White to off-white
SMILES

O=C(NOCCCCCC(NO)=O)C1=CC(C)=CC(C)=C1
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (31)

All WB

Sort by:

Journal Impact Factor

Theranostics

HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. [Abstract]

2022 Jan 31;12(5):2080-2094. PMID: 35265200
Cell Death Dis

Deacetylation of TALDO1 by HDAC6 promotes glycolysis and nasopharyngeal carcinoma progression through a moonlighting function. [Abstract]

2025 Oct 21;16(1):743. PMID: 41120289
Cell Death Dis

HAT1/HDAC2 mediated ACSL4 acetylation confers radiosensitivity by inducing ferroptosis in nasopharyngeal carcinoma. [Abstract]

2025 Mar 6;16(1):160. PMID: 40050614
Cancer Lett

HDAC4 mediated LHPP deacetylation enhances its destabilization and promotes the proliferation and metastasis of nasopharyngeal carcinoma. [Abstract]

2023 May 28:562:216158. PMID: 37023940
Acta Biomater

Synergistic effects of mechanical stimulation and crimped topography to stimulate natural collagen development for tendon engineering. [Abstract]

2022 Jun;145:297-315. PMID: 35470072
J Transl Med

HDAC4 induces the development of asthma by increasing Slug-upregulated CXCL12 expression through KLF5 deacetylation. [Abstract]

2021 Jun 12;19(1):258. PMID: 34118928
Oncogene

HDAC1/2-mediated deacetylation of KLF9 promotes the malignant progression of nasopharyngeal carcinoma via CDH17. [Abstract]

2025 Sep;44(35):3183-3198. PMID: 40615689
EMBO J

Acetylation of TIR domains in the TLR4-Mal-MyD88 complex regulates immune responses in sepsis. [Abstract]

2024 Nov;43(21):4954-4983. PMID: 39294473
J Ethnopharmacol

The activation of histone deacetylases 4 prevented endothelial dysfunction: A crucial mechanism of HuangqiGuizhiWuwu Decoction in improving microcirculation dysfunction in diabetes. [Abstract]

2023 May 10:307:116240. PMID: 36764560
JCI Insight

Transcriptional control of a collagen deposition and adhesion process that promotes lung adenocarcinoma growth and metastasis. [Abstract]

2022 Jan 11;7(1):e153948. PMID: 34874914
Biochem Pharmacol

H1.0 modulates IL-6 expression and paclitaxel resistance via HDAC5 in ovarian cancer cells. [Abstract]

2025 Jun:236:116876. PMID: 40112929
Life Sci

Histone deacetylase inhibitor LMK-235-mediated HO-1 expression induces apoptosis in multiple myeloma cells via the JNK/AP-1 signaling pathway. [Abstract]

2019 Apr 15:223:146-157. PMID: 30876940
Life Sci

Up-regulation of HO-1 promotes resistance of B-cell acute lymphocytic leukemia cells to HDAC4/5 inhibitor LMK-235 via the Smad7 pathway. [Abstract]

2018 Aug 15:207:386-394. PMID: 29886060

LMK-235 purchased from MedChemExpress. Usage Cited in: Life Sci. 2018 Aug 15:207:386-394. [Abstract]

The protein levels of HDAC4, HDAC5, HO-1, histone 3 acetylation, histone 4 acetylation and Smad7 in CCRF-SB cells are detected by Western blot after LMK-235 treatment at 0.25, 0.5, 1, 2 and 4 μM for 24 h. β-Actin is used as internal reference.
Commun Biol

Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia. [Abstract]

2024 Oct 4;7(1):1257. PMID: 39362994
Cancer Biol Ther

Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism. [Abstract]

2018;19(9):825-834. PMID: 29969367

LMK-235 purchased from MedChemExpress. Usage Cited in: Cancer Biol Ther. 2018;19(9):825-834. [Abstract]

OCILY10 cells are treated with different concentration of LMK-235 (0.5, 1.0, 1.5, 2.0 and 2.5 μM) for 24 hours,24 hours, 36 hours and 48 hours, and HDAC4 and HDAC5 protein levels are examined by Western blot .All experiments are conducted three times.

LMK-235 purchased from MedChemExpress. Usage Cited in: Cancer Biol Ther. 2018;19(9):825-834. [Abstract]

OCI-LY3 cells are treated with different concentration of LMK-235 (0.5, 1.0, 1.5, 2.0 and 2.5 μM) for 24 hours,24 hours, 36 hours and 48 hours, and HDAC4 and HDAC5 protein levels are examined by Western blot .All experiments are conducted three times.
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Cell Signal

HDAC5 deacetylates c-Myc and facilitates cell cycle progression in hepatocellular carcinoma cells. [Abstract]

2024 Sep 5:111386. PMID: 39243916
Development

Inhibition of HDAC4 in granulosa cells improved co-cultured oocyte maturation in vitro independent of LH in porcine. [Abstract]

2025 Apr 1;152(7):dev204618. PMID: 40066659
Funct Integr Genomics

Leptin drives glucose metabolism to promote cardiac protection via OPA1-mediated HDAC5 translocation and Glut4 transcription. [Abstract]

2025 Jan 29;25(1):28. PMID: 39875704
Insect Sci

AMPK regulates HIF-1α to induce pupal diapause in the cotton bollworm, Helicoverpa armigera. [Abstract]

2025 May 6. PMID: 40329626
Orphanet J Rare Dis

HDAC5 inhibition attenuates ventricular remodeling and cardiac dysfunction. [Abstract]

2023 Sep 4;18(1):266. PMID: 37667300
Exp Cell Res

Diacylglycerol kinase γ predicts prognosis and functions as a tumor suppressor by negatively regulating glucose transporter 1 in hepatocellular carcinoma. [Abstract]

2018 Dec 15;373(1-2):211-220. PMID: 30399372
Blood Neoplasia

From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models. [Abstract]

2026 Apr 9;3(3):100230. PMID: 42294111
bioRxiv

2025 Aug 25.
bioRxiv

2025 Aug 21.
bioRxiv

Multiplexed single-cell lineage tracing of mitotic kinesin inhibitor resistance in glioblastoma. [Abstract]

2023 Sep 12:2023.09.09.557001. PMID: 37745469
bioRxiv

2023 Jun 6.
Research Square Print

2023 Mar 9.
Research Square Print

2023 Mar 23.
Aging

Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma. [Abstract]

2021 May 28;13(11):15336-15352. PMID: 34047714
Patent

US20180263995A1.

Solvant et solubilité

In Vitro:

DMSO : 175 mg/mL (594.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3973 mL

16.9866 mL

33.9732 mL

5 mM

0.6795 mL

3.3973 mL

6.7946 mL

10 mM

0.3397 mL

1.6987 mL

3.3973 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (16.99 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (16.99 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (16.99 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[1]

The rate of cell survival under the action of test substances is evaluated by an improved MTT assay. The assay is based on the ability of viable cells to metabolize yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to violet formazan that can be detected spectrophotometrically. In brief, A2780, Cal27, Kyse510, and MDA-MB-231 cell lines are seeded at a density of 5000, 7000, 8000, and 10 000 cells/well in 96-well plates. After 24 h, cells are exposed to increased concentrations of the test compounds. Incubation is ended after 72 h, and cell survival is determined by addition of MTT solution (5 mg/mL in phosphate buffered saline). The formazan precipitate is dissolved in DMSO. Absorbance is measured at 544 and 690 nm in a FLUOstar microplate reader^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (275 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Marek L, et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013 Jan 24;56(2):427-36. [Content Brief]

[2]. Li A, et al. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget. 2016 Jun 21;7(25):37966-37978. [Content Brief]

[3]. Trazzi S, et al. HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. Hum Mol Genet. 2016 Sep 15;25(18):3887-3907. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3973 mL	16.9866 mL	33.9732 mL	84.9329 mL
	5 mM	0.6795 mL	3.3973 mL	6.7946 mL	16.9866 mL
	10 mM	0.3397 mL	1.6987 mL	3.3973 mL	8.4933 mL
	15 mM	0.2265 mL	1.1324 mL	2.2649 mL	5.6622 mL
	20 mM	0.1699 mL	0.8493 mL	1.6987 mL	4.2466 mL
	25 mM	0.1359 mL	0.6795 mL	1.3589 mL	3.3973 mL
	30 mM	0.1132 mL	0.5662 mL	1.1324 mL	2.8311 mL
	40 mM	0.0849 mL	0.4247 mL	0.8493 mL	2.1233 mL
	50 mM	0.0679 mL	0.3397 mL	0.6795 mL	1.6987 mL
	60 mM	0.0566 mL	0.2831 mL	0.5662 mL	1.4155 mL
	80 mM	0.0425 mL	0.2123 mL	0.4247 mL	1.0617 mL
	100 mM	0.0340 mL	0.1699 mL	0.3397 mL	0.8493 mL

Keywords

LMK-235

31 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

LMK-235

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Osteogenesis Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) LMK-235

Voir tous les produits spécifiques à Isoform HDAC

Activité biologique

Chemical Information

Publications (31)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

LMK-235

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Osteogenesis Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) LMK-235

Voir tous les produits spécifiques à Isoform HDAC

Activité biologique

Chemical Information

Publications (31)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

LMK-235 Related Classifications

HY-18998 Related Classifications